Browse by author
Lookup NU author(s): Professor Robert Wilkinson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Renal effects of amlodipine in normotensive renal transplant recipients. The use of cyclosporin A (CsA) has improved the success of renal transplantation, but is associated with hypertension and significant renal toxicity. Previous reports suggest that calcium channel blockers may be useful in opposing the adverse effects of CsA. We have evaluated the effects of amlodipine (5 mg, once daily for 8 weeks) on renal function in 27 normotensive renal transplant recipients with stable renal function, in a double-blind, placebo-controlled, multicentre, cross over study. Amlodipine significantly reduced serum creatinine concentration relative to placebo (mean+/-SD: 168+/-65 vs 177+/- 66 mu mol/l; P=0.002) and there was a strong trend towards an increase in effective renal plasma flow on amlodipine relative to placebo (238+/-92 vs 217+/-87 ml/min; P=0.055). Glomerular filtration rate and lithium clearance were unaffected. Trough CsA brood concentration was unaffected. Amlodipine was well tolerated, with a low incidence of adverse events, and did not affect blood pressure or heart rate. In conclusion, amlodipine reduced serum creatinine in normotensive renal transplant recipients after only 8 weeks treatment, and was well tolerated in concomitant administration with CsA.
Author(s): Wilkinson R; Raman GV; Feehally J; Coates RA; Elliott HL; Griffin PJA; Olubodun JOB
Publication type: Article
Publication status: Published
Journal: Nephrology Dialysis Transplantation
Print publication date: 01/02/1999
ISSN (print): 0931-0509
ISSN (electronic): 1460-2385
Publisher: Oxford University Press
Altmetrics provided by Altmetric